购物车
- 全部删除
- 您的购物车当前为空
Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD).
Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 |
产品描述 | Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD). |
体外活性 | Zevaquenabant can simultaneously inhibit CB1 receptors and iNOS in peripheral organs[1]. |
体内活性 | Zevaquenabant (3 mg/kg; p.o.; for 28 days) improves renal morphological and functional parameters in diet-induced obese mice[1]. Animal Model: 6-week-old male C57Bl/6J mice (diet-induced obesity)[1]Dosage: 3 mg/kg Administration: P.o.; for 28 days Result: Improved kidney morphology and function in diet-induced obese mice. |
别名 | (S)-MRI-1867 |
分子量 | 547.98 |
分子式 | C25H21ClF3N5O2S |
CAS No. | 1998760-00-1 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
评论内容